NEW YORK – Mission Bio today announced an agreement with Beijing-based genomic services provider Novogene to distribute Mission Bio's Tapestri Platform in China.
Mission Bio's Tapestri Platform offers droplet-based single-cell DNA profiling for cancer cells and mutations and can detect rare cancer subclones and co-occurring mutations. The firm, a University of California, San Francisco spinout, is based in South San Francisco, California.
Financial and other terms of the deal were not disclosed.
"We are excited about our partnership with Novogene and increasing our reach into the China market," Darrin Crisitello, chief commercial officer of Mission Bio, said in a statement. "Novogene is highly regarded globally across the industry with reach into key accounts that will have significant interest in the Tapestri Platform. The adoption of this targeted single-cell DNA analysis has been strong in other parts of the world, and we expect the same uptake in the Chinese market."
"The Mission Bio Tapestri Platform has advantages over current offerings, including increased resolution down to 0.1 percent. It is synergistic to the sequencing we offer, and we are excited to be able to offer this unique technology to our customers," added Novogene Founder and CEO Ruiqiang Li.